CRO/Sponsor

Clinical Trial Supply Chain

Decentralized Clinical Trials

Early Phase Development

Investigative Sites

Protocol Design

Risk-Based Monitoring

Study Start-Up

Trial Design

Clinical Operations & Strategy

Diversity Action Plans

Industry Initiatives

Recruitment

Analytics

Electronic Data Capture

Metrics & Benchmarks

Real World Evidence

Data Management

CRAACO

Enrollment

Integrated Research

Patient Participation

Institutional Review Board & Ethics Committee

Regulatory

Artificial Intelligence/Machine Learning

eClinical

mHealth

Technology

News

Academy

Publications

All Publications

E-Books

Media

Editorial Podcasts

Editorial Videos

Peer Exchange

Practice Academy

Conferences

Conference Coverage

Conference Listing

Columns

All Columns

A Closing Thought

Clinical Trial Insights

View from Brussels

View from Washington

Resources

Advertise

Blogs

Events

Front & Center

Partner Perspectives

White Papers

Webcasts

Subscribe

Latest solutions, case studies, interviews, practical articles for clinical trials operations, data management, technology, investigative sites and services.

About

Contact Us

Editorial Contacts

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Applied Clinical Trials Online

LinkedIN

Instagram

Facebook

Youtube

Soundcloud

Threads

Spotlight

DE&I

Topic

1rem

Authors

Current industry trends align with the need for improved, fit for purpose technology.

Beyond the Horizon: A New Era for Faster, Smarter Clinical Trials

Video interview with David MacMurchy, CEO of Lightship

Accelerate Inclusive Enrollment and Delivery with Lightship

Lightship focuses on patient accessibility and centricity in clinical trials, ensuring the patient experience is a positive one. Learn more about:

Lightship's impact on achieving diversity in clinical trials by engaging underrepresented patient populations

How Lightship utilizes hybrid and decentralized trial designs to reduce patient burden

The impact a patient centric model has on clinical trial participation and outcomes

David MacMurchy, Chief Executive Officer at Lightship, offers some insights into the company's mission toward improving equity and diversity in clinical trials. 

Latest Conference Coverage

Video interview with Sepehr Shojaei, VP of Design Solutions, Lightship

Lightship's Approach to Accessible, Inclusive, and Impactful Clinical Trials

Lightship’s purpose and mission as a company

How the nursing teams and home visits help improve study participation 

The role of mobile units and how they position Lightship to improve patient accessibility

Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research organization (CRO) partners to support clinical trials that are patient-first and accessible.

Lightship’s Approach to Accessible, Inclusive, and Impactful Clinical Trials

One2Treat Trial Design

ACT: What are your primary objectives for attending SCOPE 2025, and what insights are you hoping to gain regarding trial design innovations?

Like most people coming to SCOPE, we came here to see what's driving innovations in clinical trials and operations. At SCOPE, you have hundreds of companies, vendors, and clinical startups like us, and they all present in different tracks that are of interest to us. Specifically, I’m most interested in the patient centric trial design track.

ACT: Are there any specific trends in trial design, such as decentralized trials, real-world data integration, or AI-driven protocols that you anticipate being major discussion points?

Those are all very interesting tracks that are well presented here. But as I mentioned, I'm more interested in patient centric trial design and what it entails. While those methods are used in patient centric trial design, they are not the only one that are being used. The FDA recently promoted regulations and guidance on how to include patients in clinical trial development, but they don't really say how to do it. That’s why we come to these kinds of conferences, to promote new, concrete ways on how can you include patient voices into clinical trial design and strategy.

One2Treat s attending SCOPE to explore innovations in clinical trial operations, with a strong focus on patient-centric trial design. They highlight the event’s diverse range of participants, including companies, vendors, startups, and sponsors, all contributing to discussions on trial advancements.

While decentralized trials, real-world data integration, and AI-driven protocols are major industry trends, the speaker is primarily interested in how patient voices can be effectively integrated into trial design. They note that while the FDA has recently issued guidance on patient inclusion, it lacks detailed implementation strategies. Conferences like SCOPE provide a platform to discuss concrete methods for incorporating patient perspectives into trial strategies.

Regarding partnerships, Salvaggio emphasizes the importance of collaboration with site investigators and patient representatives. These stakeholders play a crucial role in ensuring that trials are designed with patient needs and experiences in mind, ultimately improving trial success and patient engagement.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio, Senior Trial Design Lead, One2Treat, discusses the company's main goals for attending the SCOPE Summit, including patient centric trial design. 

SCOPE Summit 2025: Samuel Salvaggio Discusses One2Treat's Primary Objectives for Attending SCOPE

Dr. Peter Wahl, MLA, MS, ScD, VP and Global Head of Scientific Affairs at CorEvitas, part of the PPD™ clinical research business of Thermo Fisher Scientific, discusses the critical role of protocol-driven registries in generating regulatory grade RWE to serve multiple and evolving evidence needs across the drug development life cycle. He covers key considerations for selecting the right type of registry, explains why registry data is the gold standard in RWD, and how it contextualizes safety and effectiveness to fulfill FDA and EMA post-marketing requirements.

Bhavish Lekh

Articles

Latest Updated Articles